- Home
- SEAT vs RLAY Comparison
SEAT vs RLAY Comparison
Compare SEAT & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- RLAY
- Stock Information
- Founded
- SEAT 2001
- RLAY 2015
- Country
- SEAT United States
- RLAY United States
- Employees
- SEAT N/A
- RLAY N/A
- Industry
- SEAT Industrial Machinery/Components
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEAT Industrials
- RLAY Health Care
- Exchange
- SEAT Nasdaq
- RLAY Nasdaq
- Market Cap
- SEAT 597.1M
- RLAY 689.6M
- IPO Year
- SEAT N/A
- RLAY 2020
- Fundamental
- Price
- SEAT $4.60
- RLAY $4.40
- Analyst Decision
- SEAT Strong Buy
- RLAY Strong Buy
- Analyst Count
- SEAT 10
- RLAY 10
- Target Price
- SEAT $6.73
- RLAY $20.11
- AVG Volume (30 Days)
- SEAT 1.5M
- RLAY 2.5M
- Earning Date
- SEAT 11-07-2024
- RLAY 02-20-2025
- Dividend Yield
- SEAT N/A
- RLAY N/A
- EPS Growth
- SEAT N/A
- RLAY N/A
- EPS
- SEAT N/A
- RLAY N/A
- Revenue
- SEAT $774,076,000.00
- RLAY $10,006,000.00
- Revenue This Year
- SEAT $10.64
- RLAY N/A
- Revenue Next Year
- SEAT $4.21
- RLAY N/A
- P/E Ratio
- SEAT $27.06
- RLAY N/A
- Revenue Growth
- SEAT 13.91
- RLAY N/A
- 52 Week Low
- SEAT $3.24
- RLAY $4.01
- 52 Week High
- SEAT $6.41
- RLAY $12.14
- Technical
- Relative Strength Index (RSI)
- SEAT 71.67
- RLAY 42.74
- Support Level
- SEAT $4.45
- RLAY $4.01
- Resistance Level
- SEAT $4.78
- RLAY $4.39
- Average True Range (ATR)
- SEAT 0.29
- RLAY 0.27
- MACD
- SEAT 0.14
- RLAY 0.03
- Stochastic Oscillator
- SEAT 88.08
- RLAY 27.59
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).